You Searched For "keytruda" and got 20 results
Sort By:
1 min read
Centre gives full basic customs duty exemption on import of drugs for rare diseases
In a significant step, the Centre has given full exemption from basic customs duty on all drugs as …
2 mins read
A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year
Bob Duggan, 80, has gone from baking cookies to building robots, investing in biotech companies, an…
Theron Mohamed
1 min read
Moderna soars 24% after the drug maker posts upbeat results from cancer vaccine trial
The pharma giant said combining its cancer vaccine with Merck's Keytruda therapy reduced patients' …
Phil Rosen
2 mins read
Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccine
The move is welcomed by investors because if successful, it would help Moderna diversify its revenu…
Matthew Fox
2 mins read
Moderna just used a personalized vaccine to treat cancer, and it could signal a major breakthrough in how we treat the disease
"Now we are an oncology company," Moderna CEO Stéphane Bancel told Insider.
Andrew Dunn
2 mins read
US stocks rise but pare most gains after inflation cools in November and investors brace for final Fed decision of 2022
Nearly all of the S&P 500's sector rose Tuesday, enough to eke out a second straight advance after …
Carla Mozée
7 mins read
Big Pharma rakes in $215 billion a year in America yet pays almost no taxes
Americans are getting screwed over by Big Pharma twice: first by high drug prices and again by the …
Brad Setser,Tess Turner
4 mins read
We spoke with a key Merck executive about the strategy for its top cancer drug, a $7 billion powerhouse that could soon bring in more than $20 billion
The drugmaker has also tried to reach cancers that haven't responded well to other medicines with c…
Emma Court
4 mins read
One crucial quote from Merck CEO Ken Frazier at an event for big-time investors in Manhattan shows the US drug giant at a crossroads
After nearly a decade of leadership by Frazier, Merck is preparing for transition at the top, thoug…
Emma Court
2 mins read
Merck climbs after announcing massive growth for its top cancer drug, which is now on pace to generate $10 billion a year
The bulk of the company's sales win came from Keytruda, a cancer treatment that uses the immune sys…
Ben Winck
2 mins read
VCs warn of a glut of cancer startups
These are Insider's biggest healthcare stories for August 17.
Lydia Ramsey Pflanzer
1 min read
Merck CEO Kenneth Frazier is retiring. He is one of only 4 Black CEOs in the Fortune 500, and famously stood up to Trump over Charlottesville in 2017.
Kenneth Frazier, who has led the US pharma giant Merck for nearly 30 years, is retiring, and will b…
Kate Duffy,Reuters
2 mins read
2 massive drugmakers are locked in a battle over the market for cancer immunotherapy - Goldman analysts say one is pulling ahead
Last Thursday, Merck announced positive phase 3 results for its treatment of advanced or metastatic…
Charlotte Hu
5 mins read
'We are going to have lung cancer patients living longer and better:' A new kind of cancer treatment is about to change how we treat the disease
Progression-free survival - a clinical endpoint that basically means the cancer hasn't grown - was …
Lydia Ramsey
3 mins read
Regeneron's coming late to a group of drugs that's already worth billions - here's why the company thinks it can still compete
If it turns out that finding the cancers that are driven by the immune system is key to getting imm…
Lydia Ramsey
4 mins read
Dispensed: Young blood startup is back, a scoop about CityMD, and telling remarks from Merck's CEO
Welcome to this week's edition of Dispensed, our weekly healthcare newsletter here at Business Insi…
Zachary Tracer
5 mins read
It’s good that India wants just two GST slabs but it has to ensure it doesn’t hurt consumers
However, experts say that it could also be down to just two slabs, eventually. And the latest mo…
3 mins read
A new kind of treatment is working better than chemotherapy in some lung cancer patients
"Immunotherapy with checkpoint inhibitors will displace chemotherapy in yet another subset of patie…
Lydia Ramsey
2 mins read
A cancer-drug developer's stock just surged more than 100% after Merck agreed to a multi-billion-dollar takeover
ArQule's lead drug candidate, ARQ 531, is in Phase 2 testing as a treatment for blood cancer. The o…
Ben Winck
2 mins read
Bristol-Myers Squibb won't be going after a fast approval for its lung cancer drug
But not everybody responds to the PD-1 drugs. Just a quarter to a third of non-small cell lung canc…